Ventus Therapeutics selects potential first-in-class cGAS inhibitor as development candidate

Jan. 5, 2023

Ventus Therapeutics Inc. has nominated a potential first-in-class cyclic GMP-AMP synthase (cGAS) inhibitor, VENT-03, as the company’s first development candidate directed against cGAS.

BioWorld Science Genetic/congenital Immune Inflammatory Neurology/psychiatric

Today's news in brief

BioWorld

BioWorld briefs for Feb. 26, 2025.

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Feb. 26, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Clots and metastasis in cancer patients start in the lung

BioWorld MedTech

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...